By Laura Lutz
Des Moines, Jan. 14 - Nymox Pharmaceutical Corp. received a $15 million equity line from institutional investors, according to a news release.
The company may sell stock to the investors at a 3% discount to the market price. All of the investors have participated in previous equity financings with Nymox.
No warrants are included.
The agreement does not include restrictions on future financings.
Based in Hasbrouck, N.J., Nymox is a biotechnology company focused on needs of the aging population.
| Issuer: | Nymox Pharmaceutical Corp.
|
| Issue: | Equity line
|
| Amount: | $15 million
|
| Price: | 3% discount to market price
|
| Warrants: | No
|
| Announcement date: | Jan. 14
|
| Stock symbol: | Nasdaq: NYMX
|
| Stock price: | $5.25 at close Jan. 11
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
